AbbVie announced the U.S. FDA has approved SKYRIZI for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Recommends Shareholders Reject Tutanota’s “Mini-Tender” Offer
- AbbVie recommends shareholders reject Tutanota’s ‘mini-tender’ offer
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential
- AbbVie enters license agreement with FutureGen to develop IBD therapy
- AbbVie’s mirvetuximab soravtansine meets Phase 2 efficacy endpoint